This wealth manager just dumped his entire $3.5 million stake in the iShares Biotech ETF

• Sold 24,270 IBB shares; Estimated trade value of $3.50 million based on quarterly average price.

• The net value of the position decreased by $3.50 million.

• It represents a 3.27% change in 13F reportable assets under management.

• Rye Brook Capital now owns no shares and has no remaining value in IBB.

• The sale comes amid reduced funding; the position was 1.8% of the fund’s assets under management in the previous quarter.

• These 10 stocks could generate the next wave of millionaires ›

Rye Brook Capital LLC sold out iShares Biotech ETF (NASDAQ:IBB)liquidating 24,270 shares in an estimated $3.5 billion deal based on the quarterly average price, according to a new SEC filing.

According to a January 26, 2026 SEC filing, Rye Brook Capital LLC sold its entire stake of 24,270 shares in the iShares Biotechnology ETF. The estimated value of the transaction is $3.50 million, calculated using the average share price during the quarter. The value of the position at the end of the quarter decreased by $3.50 million. The fund reported no shares remaining after the trade.

• Rye Brook Capital exited IBB entirely.

• Main participations after the presentation:

  • NASDAQ: QQQ: $26.14 million (24% of assets under management)

  • TSX: U-UN.TO: $15.2 million (14% of AUM)

  • NASDAQ: SMH: $12.07 million (11% of assets under management)

  • NYSEMKT: KWEB: $8.01 million (7.5% of assets under management)

  • New York Stock Exchange: NXE: $7.12 million (6.6% of assets under management)

• As of January 26, 2026, the stock was priced at $175.85, up 27.4% year-over-year, with 14.48 percentage points of alpha against the S&P 500.

• The position was 1.8% of the fund’s assets under management in the previous quarter.

• The iShares Biotechnology ETF seeks to track the investment results of an index composed of U.S.-listed biotechnology stocks, with the goal of providing exposure to companies engaged in biotechnology research, development and production.

• The fund’s portfolio is primarily comprised of equities of biotechnology companies, with at least 80% of assets invested in index components and up to 20% allocated to derivatives and cash equivalents.

• Structured as a non-diversified ETF.

The iShares Biotechnology ETF offers targeted access to the U.S. biotechnology sector, providing investors with a liquid vehicle to participate in industry growth and innovation. The fund’s strategy emphasizes broad exposure to leading biotech companies, balancing established names with emerging innovators. Its scale and index-based approach enable efficient sector allocation for portfolio managers seeking specialist healthcare exposure.